HDAC5 and hepatocellular carcinoma: CD13 can promote the proliferation, invasion, cell cycle progression and sorafenib resistance of HCC cells, which is consistent with the finding that HDAC5-LSD1-Nf-κB is related to the activation of carcinogenic signaling [19].